Cyclooxygenase (COX) inhibitors lower the risk of colorectal cancer (CRC) and inhibit tumor growth in animal and cell culture models. However, their efficacy in treating existing CRC remains controversial. Previous research in our laboratory has demonstrated that stromal colonic myofibroblasts (CMFs), and not epithelial cells are the principal COX-2 expressing cells in human colonic adenomas and adenocarcinomas. Wnt/β catenin signaling is a crucial pathway for the development of CRC and over 90% of sporadic colorectal adenocarcinomas harbor activating mutations along this axis. CMFs also synthesize paracrine factors capable of augmenting or suppressing epithelial Wnt signaling. Wnt signaling is also crucial for maintenance of intestinal epithelial stem cells and we have shown that CMFs contribute to the epithelial stem cell niche of the normal colon. We have isolated CMFs from normal human colonic tissue and colorectal adenocarcinomas and have identified distinct phenotypic differences between them. In the research proposed, we will test the hypothesis that in normal colonic mucosa and colorectal cancer, alterations in paracrine Wnt/βcatenin and bone morphogenetic protein (BMP) family signaling between the colonic epithelium and myofibroblasts create a microenvironment that favors neoplasia. These alterations affect not only proliferation of the cancerous epithelium, but also tumor initiating cell population dynamics. We will test our hypothesis by achieving the following Specific Aims:
Aim 1. Determine how CMFs derived from normal or neoplastic tissues differ in their ability to modulate epithelial Wnt/βcatenin signaling directly via production of Wnt pathway agonists and antagonists.
Aim 2. Determine how CMFs derived from normal or neoplastic tissues differ in their ability to modulate epithelial Wnt/βcatenin signaling indirectly via production of BMP pathway agonists and antagonists.
Aim 3. Identify how CMF-derived Wnt and BMP modulators affect tumor initiating cell (cancer stem cell) proliferation and survival. The long term goals of this project are to develop more effective therapeutic regimens by targeting not only malignant epithelial cells, but also the tumor initiating or cancer stem cells (CSC) responsible for tumor recurrence and the stromal cells (myofibroblasts) that nurture tumor growth and progression as well as the cancer stem cell niche.

Public Health Relevance

The overall goal of this project is to develop more effective therapeutic regimens for the treatment of colorectal cancer. These regimens will target not only malignant epithelial cells of the tumor, but also the cancer stem cells responsible for tumor recurrence and the stroma that nurtures tumor progression and the cancer stem cell niche.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56DK055783-10A1
Application #
8069691
Study Section
Gastrointestinal Cell and Molecular Biology Study Section (GCMB)
Program Officer
Carrington, Jill L
Project Start
2010-09-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2012-08-31
Support Year
10
Fiscal Year
2010
Total Cost
$344,250
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Pinchuk, Irina V; Beswick, Ellen J; Saada, Jamal I et al. (2011) Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology 140:2019-30
Powell, D W; Pinchuk, I V; Saada, J I et al. (2011) Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol 73:213-37
Mifflin, R C; Pinchuk, I V; Saada, J I et al. (2011) Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol 300:G684-96
Pinchuk, I V; Mifflin, R C; Saada, J I et al. (2010) Intestinal mesenchymal cells. Curr Gastroenterol Rep 12:310-8
Mittal, Sahil; Mifflin, Randy; Powell, Don W (2009) Cancer stem cells: the other face of Janus. Am J Med Sci 338:107-12